Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma
- 20 November 2012
- journal article
- Published by Springer Science and Business Media LLC in Virchows Archiv
- Vol. 462 (1), 73-81
- https://doi.org/10.1007/s00428-012-1340-x
Abstract
The development of laryngeal squamous cell carcinomas (LSCC) is strongly influenced by the host immune system. Indoleamine 2,3-dioxygenase (IDO) can promote and maintain an immunosuppressive microenvironment which can impede the efficacy of anticancer responses. The purpose of the current study is to investigate the prognostic value of intratumoral IDO expression in LSCC. The expression of IDO protein was retrospectively assessed by immunohistochemistry in 187 LSCC patients. The potential association of tumor IDO expression with clinical parameters and tumor-infiltrating lymphocytes (TILs) was analyzed separately. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were determined by log-rank test. Multivariate logistic regression analysis was performed to determine the independent factors associated with survival. Based on the evaluation score, 90 carcinomas (48.1 %) were identified with high IDO expression and 97 carcinomas (51.9 %) showed low expression. Tumor IDO expression was not associated with clinical stage, presence of metastases, and other clinicopathological parameters. Also, high IDO expression was not correlated with tumor-infiltrating CD3+ and CD8+ TILs. Instead it was positively related with the density of FOXP3+ Tregs. Furthermore, multivariate analysis identified a significant association of overall survival and disease-free survival with tumor IDO status. IDO high expression represents a significant negative prognostic factor in patients with LSCC. Current results provide further support for using IDO as an immunotherapeutic target in LSCC. The precise role of tumoral IDO in human LSCC remains to be elucidated in the future.Keywords
This publication has 37 references indexed in Scilit:
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic PerspectivesClinical Cancer Research, 2011
- Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node MetastasisClinical and Developmental Immunology, 2011
- Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+T-Cell Functions in Esophageal Squamous Cell CarcinomaClinical and Developmental Immunology, 2011
- Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cellsJournal of Experimental & Clinical Cancer Research, 2011
- Regulatory T cells and Foxp3Immunological Reviews, 2011
- Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomasVirchows Archiv, 2009
- Increased tryptophan degradation in patients with bronchus carcinomaEuropean Journal of Cancer Care, 2009
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell CarcinomaClinical Cancer Research, 2007
- Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinomaEuropean Journal Of Cancer, 1994